DiaMedica Therapeutics

DMAC · NASDAQ

$8.67+$0.80 (+10.17%)TodayMarket closed · Oct 20, 7:30 PM ET

Prev close $7.87

DMAC analyst rating

BuyConsensus of 2 analysts over the last 12 months. 100% rate it a buy.

Strong buy0
Buy2
Hold0
Underperform0
Sell0

12-month price target · 5 analysts

Average $17.34 (+100.0% upside)

Low: $12.12
Now: $8.67
High: $26.25

Upgrades and downgrades

The latest rating actions, newest first

DMAC analyst upgrades, downgrades and rating actions
Firm	Date	Action	Rating	Price target	Hit rate
HC Wainwright & Co.	Aug 11, 2026	Maintains	Buy	$12.00	47%
Cantor Fitzgerald	Nov 14, 2025	Initiates	Overweight	$25.00	49%

The case for and against

Updated Jan 5, 2026

Bull case

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company focused on ischemic diseases, has reported positive interim results from its Phase 2 clinical trials for preeclampsia, leading to an upward revision of share price targets from $10 to $12 due to statistically significant blood pressure reductions without placental transfer. The company's lead product candidate, DM199, is anticipated to show promise in subsequent cohort enrollments for preeclampsia, further strengthening its market position. Additionally, the potential therapeutic benefits of DM199 for acute ischemic stroke patients, particularly where traditional treatments are unsuitable, enhances the company’s growth outlook and bolsters investor confidence.

Bear case

DiaMedica Therapeutics faces significant challenges in its pipeline development, particularly with its lead candidates DM199 and DM300, as prior studies in disease-modifying treatments have not successfully extended gestation in preeclampsia cases. The company is at risk of not securing adequate capital, which is critical for sustaining operational financing and advancing clinical development, particularly if the drug candidates fail to meet revenue expectations due to factors such as market size and pricing dynamics. Additionally, there are considerable safety concerns linked to DM199, including potential adverse events such as angioedema and oral candidiasis, which could hinder patient acceptance and regulatory approval.

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.